# TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

> **NCT03860038** · PHASE2 · COMPLETED · sponsor: **TJ Biopharma Co., Ltd.** · enrollment: 113 (actual)

## Conditions studied

- Multiple Myeloma in Relapse
- Refractory Multiple Myeloma

## Interventions

- **DRUG:** TJ202 and Dexamethasone

## Key facts

- **NCT ID:** NCT03860038
- **Lead sponsor:** TJ Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-28
- **Primary completion:** 2023-01-28
- **Final completion:** 2023-01-28
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2025-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03860038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03860038, "TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT03860038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*